CU20140119A7 - Agentes para tratar trastornos que implican la modulación de receptores de riandonina - Google Patents

Agentes para tratar trastornos que implican la modulación de receptores de riandonina

Info

Publication number: CU20140119A7
Authority: CU; Cuba
Prior art keywords: riandonin; receptors; agents; treating disorders; involve modulation
Prior art date: 2012-04-18

Application number

CU20140119A

Other languages

English (en)

Other versions

CU24327B1 (es

Inventor

Jiaming Yan

Sandro Belvedere

Yael Webb

Marc Bertrand

Nicole Villeneuve

Original Assignee

Servier Lab

Armgo Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-18

Filing date

2013-04-17

Publication date

2015-03-30

2013-04-17 Application filed by Servier Lab, Armgo Pharma Inc filed Critical Servier Lab

2015-03-30 Publication of CU20140119A7 publication Critical patent/CU20140119A7/es

2018-03-13 Publication of CU24327B1 publication Critical patent/CU24327B1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/841—Muscles; heart

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Oncology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Transplantation (AREA)
Hematology (AREA)

CUP2014000119A 2012-04-18 2013-04-17 Derivados de 1,4-benzotiazepina, útiles para tratar trastornos y enfermedades asociadas con los receptores de rianodina, y las composiciones farmacéuticas que les comprenden CU24327B1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261625890P	2012-04-18	2012-04-18
EP12167732.2A EP2708535A1 (en)	2012-05-11	2012-05-11	Agents for treating disorders involving modulation of ryanodine receptors
PCT/EP2013/057958 WO2013156505A1 (en)	2012-04-18	2013-04-17	Agents for treating disorders involving modulation of ryanodine receptors

Publications (2)

Publication Number	Publication Date
CU20140119A7 true CU20140119A7 (es)	2015-03-30
CU24327B1 CU24327B1 (es)	2018-03-13

Family

ID=49165460

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CUP2014000119A CU24327B1 (es)	2012-04-18	2013-04-17	Derivados de 1,4-benzotiazepina, útiles para tratar trastornos y enfermedades asociadas con los receptores de rianodina, y las composiciones farmacéuticas que les comprenden

Country Status (48)

Country	Link
US (3)	US20130281512A1 (es)
EP (2)	EP2708535A1 (es)
JP (1)	JP5965542B2 (es)
KR (1)	KR101731459B1 (es)
CN (1)	CN104350045B (es)
AP (1)	AP3591A (es)
AR (1)	AR090712A1 (es)
AU (1)	AU2013248313B2 (es)
BR (1)	BR112014025670B1 (es)
CA (1)	CA2870599C (es)
CL (1)	CL2014002756A1 (es)
CO (1)	CO7091184A2 (es)
CR (1)	CR20140476A (es)
CU (1)	CU24327B1 (es)
CY (1)	CY1115826T1 (es)
DK (1)	DK2653466T3 (es)
DO (1)	DOP2014000230A (es)
EA (1)	EA027922B1 (es)
EC (1)	ECSP14027564A (es)
ES (1)	ES2529890T3 (es)
GE (1)	GEP20186836B (es)
GT (1)	GT201400222A (es)
HR (1)	HRP20141113T8 (es)
HU (1)	HUE024284T2 (es)
IL (1)	IL235043A (es)
JO (1)	JO3070B1 (es)
MA (1)	MA37525B1 (es)
MD (1)	MD4489C1 (es)
ME (1)	ME01969B (es)
MX (1)	MX350890B (es)
MY (1)	MY167783A (es)
NI (1)	NI201400123A (es)
NZ (1)	NZ701122A (es)
PE (1)	PE20142193A1 (es)
PH (1)	PH12014502256B1 (es)
PL (1)	PL2653466T3 (es)
PT (1)	PT2653466E (es)
RS (1)	RS53711B1 (es)
RU (1)	RU2644350C2 (es)
SA (1)	SA113340479B1 (es)
SG (1)	SG11201406404YA (es)
SI (1)	SI2653466T1 (es)
TN (1)	TN2014000424A1 (es)
TW (1)	TWI507399B (es)
UA (1)	UA113759C2 (es)
UY (1)	UY34742A (es)
WO (1)	WO2013156505A1 (es)
ZA (1)	ZA201407499B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9725429B2 (en)	2013-03-15	2017-08-08	Rosalind Franklin University Of Medicine And Science	Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
EP2968229B1 (en)	2013-03-15	2019-12-04	Rosalind Franklin University of Medicine and Science	Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
ES2934319T3 (es) *	2013-07-18	2023-02-21	Baylor College Medicine	Métodos y composiciones para el tratamiento de la atrofia muscular, la debilidad muscular y/o la caquexia
WO2015197562A1 (en) *	2014-06-23	2015-12-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of disorders or diseases associated with ryanodine receptor dysfunction
JP6574773B2 (ja)	2014-07-30	2019-09-11	株式会社アエタスファルマ	１，４−ベンゾチアゼピン−１−オキシド誘導体の光学異性体、及びそれを用いた医薬組成物
CN107454842A (zh) *	2014-12-30	2017-12-08	莫尔瑟瑞克斯股份有限公司	新型钙调节剂
ES2643856B1 (es)	2016-05-24	2018-08-03	Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea	Triazoles para la regulación de la homeostasis de calcio intracelular
WO2018165171A1 (en)	2017-03-06	2018-09-13	Washington University	Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders
WO2019082940A1 (ja) *	2017-10-25	2019-05-02	学校法人順天堂	リアノジン受容体阻害薬
MX2020011065A (es)	2018-04-19	2021-01-20	Tvardi Therapeutics Inc	Inhibidores stat3.
US11026905B2 (en)	2018-04-19	2021-06-08	Tvardi Therapeutics, Inc.	STAT3 inhibitors
EP4093377A1 (en)	2020-01-24	2022-11-30	Tvardi Therapeutics, Inc.	Therapeutic compounds, formulations, and uses thereof
CN116635378A (zh) *	2020-11-06	2023-08-22	赛特凯恩蒂克公司	二环1,4-二氮杂环庚酮和其治疗用途
CN116887839A (zh) *	2021-01-08	2023-10-13	阿姆果制药有限公司	兰诺定受体调节剂的结晶形式及其用途
CN115369163A (zh) *	2021-05-17	2022-11-22	中国科学院上海营养与健康研究所	Ryr2及其下调剂在治疗转移性结直肠癌中的应用
US11717526B2 (en)	2021-05-20	2023-08-08	Armgo Pharma, Inc.	Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof
CA3176718A1 (en) *	2021-05-20	2022-11-20	Armgo Pharma, Inc.	Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof
WO2023091524A1 (en) *	2021-11-16	2023-05-25	Armgo Pharma, Inc.	Therapeutic compounds
US20230302013A1 (en) *	2022-02-09	2023-09-28	The Trustees Of Columbia University In The City Of New York	METHOD OF TREATING VIRAL-INDUCED COGNITIVE DYSFUNCTION BY TARGETING LEAKY RyR2 CHANNELS
EP4230196A1 (en)	2022-02-21	2023-08-23	Som Innovation Biotech, S.A.	Compounds for use in the treatment of dystrophinopathies
JP2025520456A (ja)	2022-06-15	2025-07-03	トゥヴァルディセラピューティクス，インク．	Ｓｔａｔ３阻害剤のプロドラッグ
EP4548971A1 (en) *	2023-11-06	2025-05-07	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin	1,4-benzothiazepines and related compounds with cyclopropanol groups as multi-targeted drugs

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0368063B1 (de) *	1988-11-05	1992-06-10	Bayer Ag	Verfahren zur Kernchlorierung von aromatischen Kohlenwasserstoffen
GB9021813D0 (en) *	1990-10-08	1990-11-21	Ici Plc	Tricyclic heterocycles
JP3497164B2 (ja)	1991-06-28	2004-02-16	スミスクライン・ビーチャム・コーポレイション	二環式フィブリノーゲン拮抗薬
SK280522B6 (sk) *	1992-11-09	2000-03-13	The Boots Company Plc	Deriváty 2,3,4,5-tetrahydro-1,4-benzotiazepínov, s
FR2752017B1 (fr)	1996-08-01	1998-10-16	Hispano Suiza Sa	Inverseur de poussee de turboreacteur a portes formant ecopes
GB9914745D0 (en)	1999-06-24	1999-08-25	Knoll Ag	Therapeutic agents
US7718644B2 (en)	2004-01-22	2010-05-18	The Trustees Of Columbia University In The City Of New York	Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) *	2005-08-25	2011-02-01	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040229781A1 (en) *	2000-05-10	2004-11-18	Marks Andrew Robert	Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US8022058B2 (en) *	2000-05-10	2011-09-20	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
US20020183307A1 (en)	2000-07-26	2002-12-05	Tremont Samuel J.	Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
NZ525928A (en)	2000-10-30	2005-06-24	Janssen Pharmaceutica Nv	Tripeptidyl peptidase inhibitors
US7544678B2 (en) *	2002-11-05	2009-06-09	The Trustees Of Columbia University In The City Of New York	Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
EP1603450A4 (en)	2003-03-07	2009-07-29	Univ Columbia	PROCEDURE BASED ON TYPE 1 RYANODIN RECEPTOR
US20090292119A1 (en) *	2003-10-07	2009-11-26	The Trustees Of Columbia University In The City Of New York	Methods for synthesizing benzothiazepine compounds
DE112005003511T5 (de)	2005-03-23	2008-04-17	Battelle Memorial Institute, Richland	RFID-System mit verbesserter Leistungsfähigkeit
US7704990B2 (en)	2005-08-25	2010-04-27	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2007127145A2 (en)	2006-04-25	2007-11-08	The Trustees Of Columbia University In The City Of New York	Methods and compositions for treatment of cardiac arrhythmia in non-human animals
WO2008060332A2 (en)	2006-06-02	2008-05-22	The Trustees Of Columbia University In The City Of New York	Methods for treating or reducing muscle fatigue
WO2008021432A2 (en)	2006-08-17	2008-02-21	The Trustees Of Columbia University In The City Of New York	Compositions and methods for treatment of conditions affecting the nervous system
WO2008021439A2 (en) *	2006-08-17	2008-02-21	The Trustees Of Columbia University In The City Of New York	Compositions and methods for treatment of cardiac hypertrophy
WO2008064264A2 (en)	2006-11-20	2008-05-29	Armgo Pharma, Inc.	In vivo methods for identifying and screening compounds that modulate calstabin binding to a ryanodine receptor
AU2009221969B2 (en)	2008-03-03	2012-04-19	Rycarma Therapeutics, Inc.	Process for preparing benzothiazepines from gamma-aminoalkylbenzenes
CN101891706B (zh) *	2010-04-09	2013-05-29	复旦大学	3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途
WO2012019076A1 (en)	2010-08-06	2012-02-09	The Trustees Of Columbia University In The City Of New York	Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury
WO2012019071A1 (en)	2010-08-06	2012-02-09	The Trustees Of Columbia University In The City Of New York	Methods of preventing and treating sarcopenia
WO2012037105A1 (en)	2010-09-14	2012-03-22	The Trustees Of Columbia University In The City Of New York	Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases

2012
- 2012-05-11 EP EP12167732.2A patent/EP2708535A1/en not_active Withdrawn
2013
- 2013-04-09 JO JOP/2013/0090A patent/JO3070B1/ar active
- 2013-04-12 UY UY0001034742A patent/UY34742A/es not_active Application Discontinuation
- 2013-04-17 CN CN201380030477.8A patent/CN104350045B/zh active Active
- 2013-04-17 BR BR112014025670-5A patent/BR112014025670B1/pt active IP Right Grant
- 2013-04-17 EA EA201401141A patent/EA027922B1/ru not_active IP Right Cessation
- 2013-04-17 RS RS20140701A patent/RS53711B1/sr unknown
- 2013-04-17 SG SG11201406404YA patent/SG11201406404YA/en unknown
- 2013-04-17 EP EP20130164051 patent/EP2653466B1/en active Active
- 2013-04-17 MD MDA20140119A patent/MD4489C1/ro not_active IP Right Cessation
- 2013-04-17 PL PL13164051T patent/PL2653466T3/pl unknown
- 2013-04-17 SI SI201330014T patent/SI2653466T1/sl unknown
- 2013-04-17 PT PT131640518T patent/PT2653466E/pt unknown
- 2013-04-17 AP AP2014008011A patent/AP3591A/xx active
- 2013-04-17 HU HUE13164051A patent/HUE024284T2/en unknown
- 2013-04-17 CU CUP2014000119A patent/CU24327B1/es unknown
- 2013-04-17 RU RU2014145939A patent/RU2644350C2/ru not_active IP Right Cessation
- 2013-04-17 NZ NZ701122A patent/NZ701122A/en unknown
- 2013-04-17 PE PE2014001612A patent/PE20142193A1/es active IP Right Grant
- 2013-04-17 JP JP2015506221A patent/JP5965542B2/ja active Active
- 2013-04-17 AR ARP130101246A patent/AR090712A1/es unknown
- 2013-04-17 CA CA2870599A patent/CA2870599C/en active Active
- 2013-04-17 DK DK13164051.8T patent/DK2653466T3/en active
- 2013-04-17 KR KR1020147032345A patent/KR101731459B1/ko active Active
- 2013-04-17 WO PCT/EP2013/057958 patent/WO2013156505A1/en not_active Ceased
- 2013-04-17 ES ES13164051.8T patent/ES2529890T3/es active Active
- 2013-04-17 TW TW102113668A patent/TWI507399B/zh active
- 2013-04-17 ME MEP-2014-147A patent/ME01969B/me unknown
- 2013-04-17 MY MYPI2014702980A patent/MY167783A/en unknown
- 2013-04-17 MX MX2014012575A patent/MX350890B/es active IP Right Grant
- 2013-04-17 AU AU2013248313A patent/AU2013248313B2/en active Active
- 2013-04-17 UA UAA201412301A patent/UA113759C2/uk unknown
- 2013-04-17 SA SA113340479A patent/SA113340479B1/ar unknown
- 2013-04-17 GE GEAP201713636A patent/GEP20186836B/en unknown
- 2013-04-18 US US13/865,359 patent/US20130281512A1/en not_active Abandoned
- 2013-11-11 US US14/076,474 patent/US8853198B2/en active Active
2014
- 2014-09-03 US US14/475,980 patent/US20140378437A1/en not_active Abandoned
- 2014-10-07 PH PH12014502256A patent/PH12014502256B1/en unknown
- 2014-10-07 IL IL235043A patent/IL235043A/en active IP Right Grant
- 2014-10-10 TN TN2014000424A patent/TN2014000424A1/fr unknown
- 2014-10-10 CO CO14224913A patent/CO7091184A2/es active IP Right Grant
- 2014-10-13 DO DO2014000230A patent/DOP2014000230A/es unknown
- 2014-10-14 CR CR20140476A patent/CR20140476A/es unknown
- 2014-10-14 CL CL2014002756A patent/CL2014002756A1/es unknown
- 2014-10-15 ZA ZA2014/07499A patent/ZA201407499B/en unknown
- 2014-10-17 GT GT201400222A patent/GT201400222A/es unknown
- 2014-10-30 NI NI201400123A patent/NI201400123A/es unknown
- 2014-11-13 MA MA37525A patent/MA37525B1/fr unknown
- 2014-11-17 EC ECIEPI201427564A patent/ECSP14027564A/es unknown
- 2014-11-18 HR HRP20141113TT patent/HRP20141113T8/hr unknown
- 2014-12-17 CY CY20141101052T patent/CY1115826T1/el unknown

Also Published As

Publication number	Publication date
CR20140476A (es)	2014-12-02
UA113759C2 (xx)	2017-03-10
MX350890B (es)	2017-09-25
HRP20141113T1 (hr)	2015-01-02
CY1115826T1 (el)	2017-01-25
HRP20141113T8 (hr)	2015-11-06
DOP2014000230A (es)	2014-12-15
CO7091184A2 (es)	2014-10-21
US20130281512A1 (en)	2013-10-24
MY167783A (en)	2018-09-25
EP2653466A1 (en)	2013-10-23
SG11201406404YA (en)	2014-11-27
CL2014002756A1 (es)	2015-06-12
EP2653466B1 (en)	2014-10-29
CA2870599C (en)	2016-08-16
UY34742A (es)	2013-11-29
DK2653466T3 (en)	2015-02-02
US20140378437A1 (en)	2014-12-25
MD20140119A2 (ro)	2015-04-30
WO2013156505A1 (en)	2013-10-24
AU2013248313B2 (en)	2016-11-10
MD4489C1 (ro)	2018-01-31
PT2653466E (pt)	2014-12-03
AU2013248313A1 (en)	2014-10-30
CA2870599A1 (en)	2013-10-24
CN104350045A (zh)	2015-02-11
RU2644350C2 (ru)	2018-02-09
EA027922B1 (ru)	2017-09-29
BR112014025670B1 (pt)	2020-06-30
TW201345900A (zh)	2013-11-16
GT201400222A (es)	2018-09-28
MD4489B1 (ro)	2017-06-30
AP3591A (en)	2016-02-15
AR090712A1 (es)	2014-12-03
JP2015514736A (ja)	2015-05-21
PL2653466T3 (pl)	2015-04-30
NZ701122A (en)	2016-07-29
ECSP14027564A (es)	2015-08-31
ES2529890T8 (es)	2015-08-24
RU2014145939A (ru)	2016-06-10
EA201401141A1 (ru)	2015-04-30
SA113340479B1 (ar)	2015-09-03
CN104350045B (zh)	2016-08-24
HK1192537A1 (en)	2014-08-22
US20140088171A1 (en)	2014-03-27
MA37525B1 (fr)	2016-12-30
KR101731459B1 (ko)	2017-04-28
GEP20186836B (en)	2018-03-26
MA37525A1 (fr)	2016-05-31
TN2014000424A1 (fr)	2016-03-30
EP2708535A1 (en)	2014-03-19
JO3070B1 (ar)	2017-03-15
HK1207073A1 (zh)	2016-01-22
HUE024284T2 (en)	2016-01-28
PE20142193A1 (es)	2014-12-31
JP5965542B2 (ja)	2016-08-10
KR20150003347A (ko)	2015-01-08
NI201400123A (es)	2015-03-05
US8853198B2 (en)	2014-10-07
AP2014008011A0 (en)	2014-10-31
CU24327B1 (es)	2018-03-13
SI2653466T1 (sl)	2015-03-31
ES2529890T3 (es)	2015-02-25
MX2014012575A (es)	2015-07-06
ZA201407499B (en)	2015-12-23
IL235043A (en)	2016-10-31
ME01969B (me)	2015-05-20
PH12014502256A1 (en)	2015-02-09
TWI507399B (zh)	2015-11-11
PH12014502256B1 (en)	2015-02-09
RS53711B1 (sr)	2015-04-30
EA201401141A8 (ru)	2015-08-31

Publication	Publication Date	Title
CO7091184A2 (es)	2014-10-21	Agentes para tratar trastornos que implican la modulación de receptores de riandonina
BR112013019683A2 (pt)	2018-07-10	agentes que modulam s1p
PT2919796T (pt)	2021-06-02	Utilização de akkermansia para o tratamento de distúrbios metabólicos
EP2839005A4 (en)	2016-10-05	MIRNA MODULATORS OF THERMOGENESIS
BR302013001048S1 (pt)	2015-08-25	Configuração aplicada em componente para lentes
HUE061618T2 (hu)	2023-07-28	Vegyület szemrendellenességek kezelésére
PT2852389T (pt)	2017-12-13	Composições que compreendem benzodiazepinas de ação rápida
EP2951148A4 (en)	2016-09-21	S1P MODULATING MEDIUM
BR112014016389A2 (pt)	2017-06-13	composições e métodos para o tratamento de doenças e distúrbios hepáticos
BR302012004997S1 (pt)	2014-10-21	"configuração aplicada em farol para motoneta"
BR112014021515A2 (pt)	2018-03-13	moduladores de receptor x hepático (lxr) para o tratamento de doenças, distúrbios e condições de pele
CL2014003052A1 (es)	2015-06-26	Anticuerpos para la neutralización de la influenza
BR112014026326A2 (pt)	2017-06-27	composição para tratamento de distúrbios metabólicos
BR112014029487A2 (pt)	2017-06-27	método para o tratamento cosmético
EP2821467A4 (en)	2015-11-11	GREASE CONTROL MEANS
PT2986325T (pt)	2019-10-09	Métodos para tratar distúrbios do ciclo da ureia
BR112015010428A2 (pt)	2017-07-11	agente terapêutico para distúrbios ceratoconjuntivos
BR112014030054A2 (pt)	2017-06-27	dispositivo de segurança para transformadores elétrico relacionado
BR112014005129A2 (pt)	2017-03-28	método para o tratamento de um reservatório de petróleo
ES1076945Y (es)	2012-08-16	Dispositivo para la vaporizacion de sustancias
CL2014003362A1 (es)	2015-08-28	Proceso para la producción de aceites de baja saturación.
ES1077555Y (es)	2012-11-06	Dispositivo de fijacion para tarimas
ES1076883Y (es)	2012-08-07	Dispositivo extraible para la sujecion de escaleras
ES1074956Y (es)	2011-10-04	Dispositivo para la iluminacion de sendas
ES1077500Y (es)	2012-10-26	Electrovalvula para la regulacion de fluidos